INTERNATIONAL & USA PRESS INQUIRIES
Please contact David Fraser for international media inquiries
Please contact Corey Henry for USA media inquiries
May 14, 2021
FDA Seeks Public Comments on PMI Application to Market IQOS 3 as Modified Risk Tobacco Product
PMI’s application requests the same reduced exposure modification orders granted on
The IQOS 3 device contains a number of technological advancements, compared to the IQOS 2.4 device, including longer battery life and quicker recharge between uses. It was authorized for sale in the
Commenting on the FDA’s action
“PMI is fully committed to a smoke-free future, one where we completely replace cigarettes with scientifically substantiated smoke-free alternatives that are a better choice for adults who would otherwise continue smoking. Our commitment to a science-based future is unmatched, having invested more than
This application underscores PMI’s on-going commitment to make new innovations available to American adult smokers through the FDA process; the confidence we have in our science; and our belief that public scrutiny and open engagement with governments is vital to achieving a smoke-free future.”
Note to Editor
The FDA’s reduced exposure marketing orders for IQOS 2.4 authorized communication of the following information:
The IQOS System heats tobacco but does not burn it.
This significantly reduces the production of harmful and potentially harmful chemicals.
Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system reduces your body’s exposure to harmful or potentially harmful chemicals.
- The IQOS System heats tobacco but does not burn it.
- IQOS is available in the U.S. market through an exclusive license with Altria Group, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005297/en/
Philip Morris International Media Office
T. +1 (202) 679 7296